可溶性sST2在急性心梗后心衰的研究进展
Research Progress of Soluble sST2 in Heart Failure after Acute Myocardial Infarction
DOI: 10.12677/acm.2025.1582384, PDF,   
作者: 董 钰, 胡 帆：西安医学院研工部，陕西 西安；陈 皓, 杨 光*：陕西省人民医院心内二科，陕西 西安
关键词: 可溶性生长刺激表达基因2蛋白；心力衰竭；急性心肌梗死；临床诊疗；sST2； Heart Failure； Acute Myocardial Infarction； Clinical Diagnosis
摘要: sST2是由ST2基因编码的一种蛋白质，包括跨模型受体和可溶性ST2 (sST2)两种亚型。ST2L可与IL-33特异性结合形成跨膜复合物，参与体内多个系统炎症和免疫性疾病的发生、发展，而sST2可作为诱骗受体与IL-33结合，阻断IL-33/ST2L信号通路。近年来，多种研究发现，sST2在急性心梗后心衰患者中的早期预测、诊疗、危险分层中起到重要作用。是可联合NT-pro BNP及肌钙蛋白应用于急性心梗后心衰早期诊断的一个新型标志物。本文系统回顾sST2在急性心梗后心衰的临床应用研究进展，以期为早期诊断、积极干预、改善病人预后及生存质量方面提供新的思路。
Abstract: sST2 is a protein encoded by the ST2 gene, which includes two subtypes, trans-body and soluble ST2 (sST2). ST2L can specifically bind to IL-33 to form a transmembrane complex and participate in the occurrence and development of multiple systemic inflammatory and immune diseases in vivo, while sST2 can act as a decoy receptor to bind to IL-33 and block the IL-33/ST2L signaling pathway. In recent years, a variety of studies have found that sST2 can be used in the early prediction, diagnosis and treatment, and risk stratification of patients with heart failure after acute myocardial infarction. It is a novel marker that can be used in combination with NT-pro BNP and troponin for the early diagnosis of heart failure after acute myocardial infarction. This article systematically reviews the research progress of the clinical application of sST2 in heart failure after acute myocardial infarction, in order to provide new ideas for early diagnosis, active intervention, and improvement of prognosis and quality of life of patients.
文章引用：董钰, 陈皓, 胡帆, 杨光. 可溶性sST2在急性心梗后心衰的研究进展[J]. 临床医学进展, 2025, 15(8): 1447-1452. https://doi.org/10.12677/acm.2025.1582384

参考文献

[1] McDonagh, T.A., Metra, M., Adamo, M., Gardner, R.S., Baumbach, A., Böhm, M., et al. (2023) 2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal, 44, 3627-3639. [Google Scholar] [CrossRef] [PubMed]
[2] Gandhi, S., Garratt, K.N., Li, S., Wang, T.Y., Bhatt, D.L., Davis, L.L., et al. (2022) Ten-Year Trends in Patient Characteristics, Treatments, and Outcomes in Myocardial Infarction from National Cardiovascular Data Registry Chest Pain-MI Registry. Circulation: Cardiovascular Quality and Outcomes, 15, e008112. [Google Scholar] [CrossRef] [PubMed]
[3] Salari, N., Morddarvanjoghi, F., Abdolmaleki, A., Rasoulpoor, S., Khaleghi, A.A., Hezarkhani, L.A., et al. (2023) The Global Prevalence of Myocardial Infarction: A Systematic Review and Meta-Analysis. BMC Cardiovascular Disorders, 23, Article No. 206. [Google Scholar] [CrossRef] [PubMed]
[4] Gulati, R., Behfar, A., Narula, J., Kanwar, A., Lerman, A., Cooper, L., et al. (2020) Acute Myocardial Infarction in Young Individuals. Mayo Clinic Proceedings, 95, 136-156. [Google Scholar] [CrossRef] [PubMed]
[5] (2016) Recent Hospitalization Trends for Acute Myocardial Infarction in Beijing. European Heart Journal, 37, 3188-3189. [Google Scholar] [CrossRef] [PubMed]
[6] 徐晓. 老年冠心病并发慢性心力衰竭患者血压变异性与其心功能的关系研究[J]. 微量元素与健康研究, 2024, 41(2): 94-95.
[7] Barnett, R. (2019) Acute Myocardial Infarction. The Lancet, 393, 2580. [Google Scholar] [CrossRef] [PubMed]
[8] Siasos, G., Tousoulis, D., Oikonomou, E., Kokkou, E., Mazaris, S., Konsola, T., et al. (2014) Novel Biomarkers in Heart Failure: Usefulness in Clinical Practice. Expert Review of Cardiovascular Therapy, 12, 311-321. [Google Scholar] [CrossRef] [PubMed]
[9] Islam, M.S. (2018) Heart Failure: From Research to Clinical Practice. In: Islam, M., Ed., Heart Failure: From Research to Clinical Practice, Springer, 1-3. [Google Scholar] [CrossRef] [PubMed]
[10] Bergmark, B.A., Mathenge, N., Merlini, P.A., Lawrence-Wright, M.B. and Giugliano, R.P. (2022) Acute Coronary Syndromes. The Lancet, 399, 1347-1358. [Google Scholar] [CrossRef] [PubMed]
[11] Fletcher, R.A., Rockenschaub, P., Neuen, B.L., Walter, I.J., Conrad, N., Mizani, M.A., et al. (2024) Contemporary Epidemiology of Hospitalised Heart Failure with Reduced versus Preserved Ejection Fraction in England: A Retrospective, Cohort Study of Whole-Population Electronic Health Records. The Lancet Public Health, 9, e871-e885. [Google Scholar] [CrossRef] [PubMed]
[12] Minicucci, M.F., Azevedo, P.S., Polegato, B.F., Paiva, S.A.R. and Zornoff, L.A.M. (2011) Heart Failure after Myocardial Infarction: Clinical Implications and Treatment. Clinical Cardiology, 34, 410-414. [Google Scholar] [CrossRef] [PubMed]
[13] Rubattu, S. and Gallo, G. (2021) The Natriuretic Peptides for Hypertension Treatment. High Blood Pressure & Cardiovascular Prevention, 29, 15-21. [Google Scholar] [CrossRef] [PubMed]
[14] Higa, Y., Nabeshima, Y., Kitano, T., Kataoka, M., Nakazono, A. and Takeuchi, M. (2022) Brain Natriuretic Peptide Measurements Using Standard Biochemical Equipment: Comparisons with Conventional Immunoassays. PLOS ONE, 17, e0268895. [Google Scholar] [CrossRef] [PubMed]
[15] Clerico, A., Passino, C., Franzini, M. and Emdin, M. (2015) Cardiac Biomarker Testing in the Clinical Laboratory: Where Do We Stand? General Overview of the Methodology with Special Emphasis on Natriuretic Peptides. Clinica Chimica Acta, 443, 17-24. [Google Scholar] [CrossRef] [PubMed]
[16] Liang, F., O’Rear, J., Schellenberger, U., Tai, L., Lasecki, M., Schreiner, G.F., et al. (2007) Evidence for Functional Heterogeneity of Circulating B-Type Natriuretic Peptide. Journal of the American College of Cardiology, 49, 1071-1078. [Google Scholar] [CrossRef] [PubMed]
[17] Groenning, B.A., Nilsson, J.C., Sondergaard, L., Kjaer, A., Larsson, H.B.W. and Hildebrandt, P.R. (2001) Evaluation of Impaired Left Ventricular Ejection Fraction and Increased Dimensions by Multiple Neurohumoral Plasma Concentrations. European Journal of Heart Failure, 3, 699-708. [Google Scholar] [CrossRef] [PubMed]
[18] Thanikachalam, P.V., Ramamurthy, S., Mallapu, P., Varma, S.R., Narayanan, J., Abourehab, M.A., et al. (2023) Modulation of IL-33/ST2 Signaling as a Potential New Therapeutic Target for Cardiovascular Diseases. Cytokine & Growth Factor Reviews, 71, 94-104. [Google Scholar] [CrossRef] [PubMed]
[19] Tsigkou, V., Siasos, G., Bletsa, E., Panoilia, M., Papastavrou, A., Kokosias, G., et al. (2020) The Predictive Role for ST2 in Patients with Acute Coronary Syndromes and Heart Failure. Current Medicinal Chemistry, 27, 4479-4493. [Google Scholar] [CrossRef] [PubMed]
[20] 杨树涵, 陈红伟, 刘艳宾. 可溶性生长刺激表达因子2对急性心肌梗死患者近期临床预后的预测价值[J]. 中国动脉硬化杂志, 2019, 27(9): 783-786, 801.
[21] Xhakollari, L., Jujic, A., Molvin, J., Nilsson, P., Holm, H., Bachus, E., et al. (2021) Proteins Linked to Atherosclerosis and Cell Proliferation Are Associated with the Shrunken Pore Syndrome in Heart Failure Patients: Shrunken Pore Syndrome and Proteomic Associations. PROTEOMICS—Clinical Applications, 15, e2000089. [Google Scholar] [CrossRef] [PubMed]
[22] 魏鹏, 孙娜, 宗斌. 可溶性ST2在原发性高血压病患者中表达及诊断价值[J]. 中国循证心血管医学杂志, 2022, 14(8): 963-966.
[23] 尹杰, 李文成, 郇雷. 扩张型心肌病患者血清半乳糖凝集素-3、分形趋化因子及可溶性sST2的变化及临床意义[J]. 中国循证心血管医学杂志, 2021, 13(3): 318-321.
[24] Obradovic, D.M., Büttner, P., Rommel, K., Blazek, S., Loncar, G., von Haehling, S., et al. (2022) Soluble ST2 Receptor: Biomarker of Left Ventricular Impairment and Functional Status in Patients with Inflammatory Cardiomyopathy. Cells, 11, Article 414. [Google Scholar] [CrossRef] [PubMed]
[25] Liew, F.Y. (2012) IL-33: A JANUS CYTokine. Annals of the Rheumatic Diseases, 71, i101-i104. [Google Scholar] [CrossRef] [PubMed]
[26] Aimo, A., Januzzi, J.L., Bayes-Genis, A., Vergaro, G., Sciarrone, P., Passino, C., et al. (2019) Clinical and Prognostic Significance of sST2 in Heart Failure. Journal of the American College of Cardiology, 74, 2193-2203. [Google Scholar] [CrossRef] [PubMed]
[27] Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T.K., et al. (2005) IL-33, an Interleukin-1-Like Cytokine That Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines. Immunity, 23, 479-490. [Google Scholar] [CrossRef] [PubMed]
[28] Stojkovic, S., Demyanets, S., Kopp, C.W., Hengstenberg, C., Wojta, J., Eichelberger, B., et al. (2020) Association of Soluble Suppression of Tumorigenesis 2 (sST2) with Platelet Activation, Monocyte Tissue Factor and Ischemic Outcomes Following Angioplasty and Stenting. Frontiers in Cardiovascular Medicine, 7, Article 605669. [Google Scholar] [CrossRef] [PubMed]
[29] Januzzi, J.L., Pascual-Figal, D. and Daniels, L.B. (2015) ST2 Testing for Chronic Heart Failure Therapy Monitoring: The International ST2 Consensus Panel. The American Journal of Cardiology, 115, 70B-75B. [Google Scholar] [CrossRef] [PubMed]
[30] Mueller, T. and Jaffe, A.S. (2015) Soluble ST2—Analytical Considerations. The American Journal of Cardiology, 115, 8B-21B. [Google Scholar] [CrossRef] [PubMed]
[31] Toshiro, K., Hiroshi, N., Tsuyoshi, Y, et al. (2003) Clinical Significance of Acute-Phase Brain Natriuretic Peptide in Acute Myocardial Infarction Treated with Direct Coronary Angioplasty. Journal of Cardiology, 42, 195-200.
[32] Sabatine, M.S., Cannon, C.P., Gibson, C.M., López-Sendón, J.L., Montalescot, G., Theroux, P., et al. (2005) Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with St-Segment Elevation. New England Journal of Medicine, 352, 1179-1189. [Google Scholar] [CrossRef] [PubMed]
[33] 孙爱梅, 刘婷,陈 还珍. 可溶性ST2对冠心病的危险分层价值及其与心功能的关系[J]. 中国心血管杂志, 2017, 22(1): 19-23.
[34] Januzzi, J.L., Peacock, W.F., Maisel, A.S., Chae, C.U., Jesse, R.L., Baggish, A.L., et al. (2007) Measurement of the Interleukin Family Member ST2 in Patients with Acute Dyspnea: Results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) Study. Journal of the American College of Cardiology, 50, 607-613. [Google Scholar] [CrossRef] [PubMed]
[35] O’Meara, E., Prescott, M.F., Claggett, B., Rouleau, J.L., Chiang, L., Solomon, S.D., et al. (2018) Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients with Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circulation: Heart Failure, 11, e004446. [Google Scholar] [CrossRef] [PubMed]
[36] El Said, N.O., El Wakeel, L.M., Khorshid, H., Darweesh, E.A.G. and Ahmed, M.A. (2021) Impact of Lipophilic vs Hydrophilic Statins on the Clinical Outcome and Biomarkers of Remodelling in Heart Failure Patients: A Prospective Comparative Randomized Study. British Journal of Clinical Pharmacology, 87, 2855-2866. [Google Scholar] [CrossRef] [PubMed]
[37] Espriella, R.D.L., Bayés-Genis, A., Revuelta-López, E., Miñana, G., Santas, E., Llàcer, P., et al. (2021) Soluble ST2 and Diuretic Efficiency in Acute Heart Failure and Concomitant Renal Dysfunction. Journal of Cardiac Failure, 27, 427-434. [Google Scholar] [CrossRef] [PubMed]

为你推荐